ConductScience.org, home

Trial · NCT07897929

Exercise and Fall Prevention for Fracture Reduction

NCT07897929, Not applicable, Not yet recruiting, Wolfgang Kemmler, PhD

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Exercise and Fall Prevention for Fracture Reduction. Trials, record NCT07897929. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897929

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Exercise and Fall Prevention for Fracture Reduction
NCT number
NCT07897929
Status
Not yet recruiting
Phases
Not applicable
Enrollment
72 participants, estimated
Lead sponsor
Wolfgang Kemmler, PhD
Conditions
Osteopenia, Osteoporosis, High Fall Risk
Interventions
Guideline-based home exercise training
First posted
2026-10-27
Last updated
2026-10-29

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChanges of chair rise test performanceChanges in the 5tStS from the baseline measurement to the 16-week follow-up (FU) assesmentTime for the 5 times sit to stand test (5tSTS) in s
PrimaryChanges in static balance performanceChanges in balance performance from the baseline measurement to the 16-week follow-up (FU) assessment.Balance performance applying the modified balance test based on the Short Physical Performance Battery (SPPB). Score from 0-4 with higher values indicationg better static balance
SecondaryChanges in the timed up and go test (TUG)Changes in the TUG test results from the baseline measurement to the 16-week follow-up.TUG: Time needed to stand up, walk 3 meters, turn, return, and sit down (in s)
SecondaryChanges in habitual walking speedChanges in the habitual walking speed from the baseline measurement to the 16-week follow-up.Habitual walking speed over 10 metres, measured using photoelectric sensors (in s)
SecondaryChanges in maximum strength of the hip- and leg-extensorsChanges in the isokinetic maximum strength of the hip- and leg-extensors from the baseline measurement to the 16-week follow-up.Isokinetic maximum strength of the hip- and leg-extensors as determined by an isokinetic leg press (NM)
SecondaryChange in maximum trunk extensors strengthChange in the maximum isometric strength of the trunk extensors from the baseline measurement to the 16-week follow-up.Maximum isometric strength of the trunk extensors (kg) as determined by a Dr. Wolff BackCheck
SecondaryChanges in fear of fallingChange in FES I from the baseline measurement to the 16-week follow-up.Fear of falling as determined by the "Short Falls Efficacy Scale-International" (FES I). 7 Items, Score from 7-28, with higher scores indicating higher concerns of falling
SecondaryChanges in bone formation biomarkersChange in PINP from the baseline measurement to the 16-week follow-up.
Changes in the bone formation marker "Procollagen Type I N-terminal Propeptide" (PINP, ng/ml)) as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Note: Only in women not receiving medication for osteoporosis
SecondaryChanges in bone resorption biomarkersChange in CTX from the baseline measurement to the 16-week follow-up.
Changes in the bone resorption marker "C-terminal telopeptide of type I collagen" (CTX, ng/ml) as determined by Enzyme-Linked Immunosorbent Assay (ELISA). Note: Only in women not receiving medication for osteoporosis
SecondaryChanges in fat free massChange in FFM from the baseline measurement to the 16-week follow-up.Fat free mass (FFM, kg, g) as determined by Bioelectrical Impedance Analysis (BIA)

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMIDListed as
41699562BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07897929

GET https://conductscience.org/api/trials/v1/NCT07897929/registered